PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Bettinger, D.* ; Pinato, D.J.* ; Schultheiss, M.* ; Sharma, R.* ; Rimassa, L.* ; Pressiani, T.* ; Burlone, M.E.* ; Pirisi, M.* ; Kudo, M.* ; Park, J.W.* ; Buettner, N.* ; Neumann-Haefelin, C.* ; Boettler, T.* ; Abbasi-Senger, N.* ; Alheit, H.* ; Baus, W.* ; Blanck, O.* ; Gerum, S.* ; Guckenberger, M.* ; Habermehl, D. ; Ostheimer, C.* ; Riesterer, O.* ; Tamihardja, J.* ; Grosu, A.-L.* ; Thimme, R.* ; Brunner, T.B.* ; Gkika, E.*

Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: A propensity score analysis.

Liver cancer 8, 281–294 (2018)
Verlagsversion Postprint DOI PMC
Open Access Gold
Background and Aims: Stereotactic body radiation therapy (SBRT) has emerged as a safe and effective treatment for patients with hepatocellular carcinoma (HCC), but its role in patients with advanced HCC is not yet defined. In this study, we aim to assess the efficacy and safety of SBRT in comparison to sorafenib treatment in patients with advanced HCC. Methods: We included 901 patients treated with sorafenib at six tertiary centers in Europe and Asia and 122 patients treated with SBRT from 13 centers in Germany and Switzerland. Medical records were reviewed including laboratory parameters, treatment characteristics and development of adverse events. Propensity score matching was performed to adjust for differences in baseline characteristics. The primary endpoint was overall survival (OS) and progression-free survival. Results: Median OS of SBRT patients was 18.1 (10.3-25.9) months compared to 8.8 (8.2-9.5) in sorafenib patients. After adjusting for different baseline characteristics, the survival benefit for patients treated with SBRT was still preserved with a median OS of 17.0 (10.8-23.2) months compared to 9.6 (8.6-10.7) months in sorafenib patients. SBRT treatment of intrahepatic lesions in patients with extrahepatic metastases was also associated with improved OS compared to patients treated with sorafenib in the same setting (17.0 vs. 10.0 months, p = 0.012), whereas in patients with portal vein thrombosis there was no survival benefit in patients with SBRT. Conclusions: In this retrospective comparative study, SBRT showed superior efficacy in HCC patients compared to patients treated with sorafenib.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
0.000
3.300
13
19
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Hepatocellular Carcinoma ; Overall Survival ; Propensity Score Analysis ; Sorafenib ; Stereotactic Body Radiation Therapy; Clinical-practice Guidelines; Quality-of-life; Transarterial Chemoembolization; Liver-tumors; Phase-i; Radiotherapy; Abscopal; Outcomes; Bridge; Efficacy
Sprache englisch
Veröffentlichungsjahr 2018
HGF-Berichtsjahr 2018
ISSN (print) / ISBN 2235-1795
e-ISSN 1664-5553
Zeitschrift Liver cancer
Quellenangaben Band: 8, Heft: 4, Seiten: 281–294 Artikelnummer: , Supplement: ,
Verlag Karger
Verlagsort Basel ; Freiburg
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Radiation Medicine (IRM)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Radiation Sciences
PSP-Element(e) G-501300-001
DOI 10.1159/000490260
WOS ID WOS:000477587300005
Scopus ID 85049915849
PubMed ID 31602371
Erfassungsdatum 2018-07-25
[➜Korrektur melden]